ArticleBlood advances2025
Implementing ASH's guidelines for acute medical care for incarcerated children and adults with sickle cell disease.
Article in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractBetween 2019 and 2021, the American Society of Hematology (ASH) developed clinical guidelines for managing sickle cell disease (SCD), covering acute pain, acute neurological events, and other complications. However, these guidelines lacked implementation strategies for incarcerated individuals, a vulnerable group with unique challenges. In 2024, an ASH special panel of SCD and carceral health experts convened to address acute SCD care in custody settings, emphasizing timely access to emergency care, including acute management for acute strokes, pain management, and fever evaluation. The ASH special panel recommended prearranged emergency plans for transfer to specialized facilities, continuity of care with SCD specialists, and adherence to community-level care standards. Limitations included insufficient population data and absent chronic care guidelines. The ASH special panel urged that future ASH guidelines address SCD management tailored to carceral settings to reduce morbidity and ensure equitable care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.